Document:

Exhibit 10.2

 

PURCHASE AGREEMENT

 

A.            This PURCHASE
AGREEMENT (the “Agreement”),
dated March 19, 2004, is made and entered into by and among CRIIMI MAE Inc., a
Maryland corporation (the “Corporation”), and Pilot Advisors, L.P., a Delaware
limited partnership (the “Adviser”), on behalf of the Accounts (as hereinafter
defined).

 

RECITALS

 

A.            The
Corporation desires, upon the terms and subject to the conditions contained
herein, to issue and sell to the Adviser, on behalf of certain investment
advisory accounts that the Adviser advises (each, an “Account” and collectively, the “Accounts”), 76,050 shares of
the Corporation’s Series B Cumulative Convertible Preferred Stock, par value
$0.01 per share (the “Offered Shares”).

 

B.            The
Adviser (on behalf of the Accounts) desires to purchase the Offered Shares on
the terms and subject to the conditions set forth in this Agreement.

 

C.            Such
purchase and sale will be made pursuant to a registration statement on Form S-3
(File No. 333-112259) (the “Registration Statement”), including the base prospectus
included therein (the “Base Prospectus”) and the prospectus supplement dated
the date hereof relating to the Offered Shares, which prospectus supplement and
Base Prospectus are referred to herein collectively as the “Prospectus.”

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants and agreements contained in this Agreement,
the parties agree as follows:

 

1.             Issuance
and Sale of the Offered Shares. 
Subject to the terms and conditions set forth herein and in reliance
upon the respective representations and warranties of the parties set forth
herein, the Corporation hereby agrees to issue and sell to the Adviser (on
behalf of the Accounts), and the Adviser (on behalf of the Accounts) hereby agrees
to purchase from the Corporation, the Offered Shares for $25.42 per Offered
Share ($1,933,191.00 in aggregate, referred to herein as the “Purchase Price”).

 

2.             Delivery of the Offered Shares
at the Closing.  Subject to the
terms and conditions contained herein, the closing of the purchase and sale of
the Offered Shares to be acquired by the Adviser (on behalf of the Accounts)
from the Corporation under this Agreement (the “Closing”) shall take place at the offices of
Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, NY  10019 at 9:00 A.M. (New York time) on March
23, 2004 or at such other time and date (the “Closing Date”) agreed upon by the Corporation
and the Adviser.  At the Closing, the
Corporation shall deliver to the Adviser

 

 

(on behalf of the Accounts) the
Offered Shares by notation on the registry of the Corporation’s transfer agent
against the wire transfer by the Adviser on the Closing Date of the Purchase
Price to the Corporation’s account.

 

3.             Adviser
Representations and Warranties.  The
Adviser represents and warrants to the Corporation that the following
statements are true and correct on the date hereof and will be true and correct
on the Closing Date.

 

3.1           The
Adviser and, to the knowledge of the Adviser, each holder of an Account, who is
not an individual, is duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization.  The Adviser is registered as an investment
adviser under the Investment Advisors Act of 1940, as amended, with assets
under management of not less than $1,000,000.

 

3.2           The
Adviser:  (a) acts as a fiduciary
and has been granted investment control over each Account and, pursuant to such
investment control, is authorized to effect the purchase of the Offered Shares
as contemplated hereby; (b) is purchasing the Offered Shares on behalf of the
Accounts in the ordinary course of its business as a registered investment
adviser; (c) is not an underwriter (as defined in Section 2(a) of the
Securities Act of 1933, as amended (the “Securities Act”)) of the Offered Shares; (d) has not
received, directly or indirectly, any commission or other remuneration in
connection with the offer, purchase or sale of the Offered Shares; and (e) has
not received, directly or indirectly, any compensation in connection with the
transaction contemplated by this Agreement other than the advisory fees payable
pursuant to the investment advisory agreements entered into between Adviser and
each Account in the ordinary course of the Adviser’s business as a registered
investment adviser.

 

3.3           None
of (a) the Adviser and its affiliates (as defined under the Securities Exchange
Act of 1934, as amended) (each an “Affiliate” and collectively, the “Affiliates”), (b) to the knowledge of the Adviser,
any Account and its Affiliates, or (c) to the knowledge of the Adviser, the
Adviser and its Affiliates and the Accounts and their respective Affiliates
considered as a whole, is:  (i) a
“Related Party” (as such term is defined in Rule 312.03(b) of the Rules of the
New York Stock Exchange, Inc. (the “NYSE”)) of the Corporation; (ii) a subsidiary, affiliate
or other closely related person of a Related Party of the Corporation; (iii) a
holder of an interest equal to or more than either five percent of the number
of shares of issued and outstanding (calculated in accordance with Rule
312.04(c) of the NYSE) common stock of the Corporation or five percent of the
“Voting Power Outstanding” (as such term is defined in Rule 312.04(e) of the
Rules of the NYSE) of the Corporation; or (iv) a company or entity in which a
Related Party of the Corporation has a substantial direct or indirect interest
(as such terms are used in Rule 312.03(b)(3) of the Rules of the NYSE).

 

2

 

3.4           Contemporaneous
with or prior to receiving this Agreement, the Adviser received the Base
Prospectus and prior to executing and delivering this Agreement, the Adviser
received the Prospectus.  Other than the
Prospectus, neither the Adviser, any of its Affiliates nor to the knowledge of
the Adviser, the Accounts or their respective Affiliates has received any other
prospectus or written offering material relating to the Offered Shares, whether
from the Corporation or any underwriter or placement agent.

 

3.5           The Adviser has all requisite power
and authority to enter into and perform its obligations under this Agreement.
The execution, delivery and performance by the Adviser of this Agreement have
been duly authorized by all necessary action. This Agreement has been duly and
validly executed and delivered by the Adviser and constitutes the legal, valid
and binding obligation of the Adviser and the Accounts, enforceable against it
and them in accordance with its terms.

 

3.6           The execution, delivery and
performance of this Agreement do not and will not (with or without the passage
of time or the giving of notice):  (a)
violate or conflict with the organizational documents of the Adviser or, to the
knowledge of the Adviser, any Account; (b) violate or conflict with any law
binding upon the Adviser or, to the knowledge of the Adviser, any Account; (c)
violate or conflict with the investment policies of any Account agreed upon by
the holder of such Account and the Adviser; or (d) require any consent, notice,
authorization, waiver by or filing with any governmental agency, administrative
body or other third party to be obtained or made by the Adviser or, to the
knowledge of the Adviser, any Account.

 

4.             Corporation’s
Representations and Warranties.  The
Corporation represents and warrants to the Adviser that the following
statements are true and correct on the date hereof and will be true and correct
on the Closing Date.

 

4.1           The
Registration Statement has been declared effective by the Securities and
Exchange Commission (the “SEC”).

 

4.2           To
the Corporation’s knowledge, no stop order suspending the effectiveness of the
Registration Statement has been issued and no proceeding for that purpose has
been initiated or threatened by the SEC.

 

4.3           The
Corporation has delivered the Prospectus to the Adviser.  Other than the Prospectus, the Corporation
has not delivered to the Adviser or any of its Affiliates any other prospectus
or written offering material relating to the Offered Shares, whether directly
or through any underwriter or placement agent.

 

4.4                
The Registration Statement, in the form
in which it became or becomes effective and also in such form as it may be when
any post-effective amendment thereto shall become effective and the Prospectus
and any amendment

 

3

 

or supplement
thereto, when filed with the SEC, complied or will comply in all material
respects with the provisions of the Securities Act and the rules promulgated
thereunder.

 

4.5           The
Offered Shares are duly authorized for issuance and, upon payment of the
Purchase Price as contemplated by this Agreement, will be validly issued and
fully paid and non-assessable and will conform in all material respects to the
description thereof set forth in the Prospectus.

 

4.6           The Corporation is duly organized,
validly existing and in good standing under the laws of the jurisdiction of its
incorporation.

 

4.7           The Corporation has all requisite
corporate power and authority to enter into and perform its obligations under
this Agreement. The execution, delivery and performance by the Corporation of
this Agreement have been duly authorized by all necessary action. This
Agreement has been duly and validly executed and delivered by the Corporation
and constitutes the legal, valid and binding obligation of the Corporation,
enforceable against it in accordance with its terms.

 

4.8           The execution, delivery and
performance of this Agreement do not and will not (with or without the passage
of time or the giving of notice):  (a)
violate or conflict with the articles of incorporation or bylaws of the
Corporation; (b) violate or conflict with any law binding upon the Corporation;
(c) violate or conflict with, result in a breach of, constitute a default or
otherwise cause any loss of benefit under any material agreement or other
material obligation to which the Corporation is a party, or by which it or any
of its assets are otherwise bound; (d) result in the creation of any
encumbrance pursuant to, or give rise to any penalty, acceleration of remedies,
right of termination or otherwise cause any alteration of any rights or
obligations of any party under any material contract to which the Corporation
is a party or by which its assets are otherwise bound; or (e) require any
consent, notice, authorization, waiver by or filing with any governmental
agency, administrative body or other third party, except for the filing of the
Registration Statement and the Prospectus with the SEC.

 

5.             Conditions
to Adviser’s Obligations.  The
obligations of the Adviser (on behalf of the Accounts) are subject to the
satisfaction or waiver of the following conditions:

 

5.1           Receipt
by the Adviser from the Corporation of notice from the NYSE that the Offered
Shares have been duly listed on such exchange, subject to notice of issuance;

 

5.2           No stop order
suspending the effectiveness of the Registration Statement has been issued and
no proceeding, investigation or other

 

4

 

inquiry with respect to the Offered Shares or
the Registration Statement has been initiated or threatened by the SEC;

 

5.3           The
Adviser has received an officer’s certificate from the Corporation dated as of
the Closing Date stating that, as of the Closing Date, (a) the representations
and warranties set forth in Section 4 are true and correct in all
material respects as of the Closing Date;

 

5.4           The
issuance and sale of the Offered Shares as contemplated hereby does not violate
any federal or state law, rule or regulation; and

 

5.5           The
Corporation has filed the Prospectus with the SEC under Rule 424(b) promulgated
under the Securities Act.

 

6.             Conditions
to Corporation’s Obligations.  The
obligations of the Corporation are subject to the satisfaction or waiver of the
following conditions:

 

6.1           Receipt
by the Corporation of notice from the NYSE that the Offered Shares have been
duly listed on such exchange, subject to notice of issuance;

 

6.2           No
stop order suspending the effectiveness of the Registration Statement has been
issued and no proceeding, investigation or other inquiry with respect to the
Offered Shares or the Registration Statement has been initiated or threatened
by the SEC;

 

6.3           The
issuance and sale of the Offered Shares as contemplated hereby does not violate
any federal or state law, rule or regulation; and

 

6.4           The
Corporation has received an officer’s certificate from the Adviser dated as of
the Closing Date stating that the representations and warranties set forth in Section
3 are true and correct in all material respects as of the Closing Date.

 

7.             Corporation
Covenant  The Corporation will use
commercially reasonable efforts to satisfy the conditions to Closing set forth
in Section 5.

 

8.             Adviser
Covenant.  The Adviser will use
commercially reasonable efforts to satisfy the conditions to Closing set forth
in Section 6.4.

 

9.             Termination.  Either party hereto may terminate this
Agreement if the conditions set forth in Sections 5 and 6 are not
satisfied or waived by 5:00 P.M. New York time on March 31, 2004 (or such later
date and/or time agreed upon by the Corporation and the Adviser).  Upon any such termination, the provisions of
this

 

5

 

Agreement (other than this Section
9) shall be of no further force or effect and neither the Corporation, the
Adviser nor any of the Accounts shall have any rights or obligations under this
Agreement (except as provided in this Section 9).

 

10.           Notices.  All notices, requests, consents and other
communications hereunder shall be in writing, shall be mailed by first-class
registered or certified airmail, or nationally recognized overnight express
courier postage prepaid, and shall be deemed given when so mailed and shall be
delivered as addressed as follows:

 

if to the
Corporation, to:

 

CRIIMI MAE
Inc.

11200 Rockville
Pike

Rockville,
MD  20852

Attention:  Chief Financial Officer

 

with a copy (which shall not constitute
notice) to:

 

Venable LLP

Two Hopkins
Plaza – Suite 1800

Baltimore,
MD  21201-2978

Attention:  Thomas D. Washburne, Jr., Esq.

 

or to such other person at such other place
as the Corporation shall designate to the Adviser in writing; and

 

if to the
Adviser:

 

Pilot
Advisors, L.P.

220 East 42nd
Street

29th
Floor

New York,
NY  10017

Attention:  Arthur Winston

 

with a copy
(which shall not constitute notice) to:

 

Goodkind
Labaton Rudoff & Sucharow LLP

100 Park
Avenue

New York, NY
10017-5563

Attention:  Michael Grandis

 

or to such other person at such other place
as the Adviser shall designate to the Corporation in writing.

 

11.           Other
Matters.  This Agreement may not be
modified or amended except pursuant to an instrument in writing signed by the
Corporation and the Adviser.  The

 

6

 

headings of the various
sections of this Agreement have been inserted for convenience of reference only
and shall not be deemed to be part of this Agreement.  In case any provision contained in this Agreement should be
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability
of the remaining provisions contained herein shall not in any way be affected
or impaired thereby.  This Agreement
shall be governed by and construed in accordance with the laws of the State of
Maryland (without regard to the laws relating to conflicts of laws of such
state) and the federal laws of the United States of America.  This Agreement may be executed in two or
more counterparts, each of which shall constitute an original, but all of which
when taken together, shall constitute but one instrument, and shall become
effective when one or more counterparts have been signed by each party hereto
and delivered to the parties parties.

 

[The next page is the signature page.]

 

7

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed by their duly authorized representatives
as of the day and year first above written.

 

	
   

  	
  CRIIMI MAE Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Mark R. Jarrell

  	
   

  
	
   

  	
  Name:

  	
  Mark R. Jarrell

  	
   

  
	
   

  	
  Title:

  	
  President

  	
   

  
	
   

  	
   

  	
  and Chief Operating Officer

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  PILOT ADVISORS, L.P.

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Arthur M. Winston

  	
   

  
	
   

  	
  Name:

  	
  Arthur M. Winston

  	
   

  
	
   

  	
  Title: 

  	
  President

  	
   

  
						

 

8Exhibit
10.1

 

*** TEXT OMITTED AND FILED
SEPARATELY

CONFIDENTIAL TREATMENT REQUESTED

Under 17
C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

CYMER CORPORATION
and INTEL CORPORATION

 

DEVELOPMENT
AGREEMENT

 

This Agreement
(the “Agreement”) is entered into as of January 23, 2004 (“Effective Date”) by
and between Cymer, Inc., a Nevada corporation, having a place of business at
17075 Thornmint Court, San Diego, CA  
92127 and its wholly owned subsidiaries (hereinafter “Cymer”), and Intel
Corporation, a Delaware corporation, having its principal place of business at
2200 Mission College Blvd., Santa Clara CA 95052 and its subsidiaries
(hereinafter “Intel”). Cymer and Intel are sometimes referred to as a “Party”
and collectively referred to as the “Parties”.

 

RECITALS

 

WHEREAS, Intel and Cymer have agreed to
certain commercial provisions, including without limitation the acceleration of
Cymer’s Extreme Ultraviolet (“EUV”) source development program to intersect
with Intel’s process roadmap needs by developing and making available under
reasonable commercial terms to Intel a 15 – 20W EUV source, a 50W EUV source,
and a HVM EUV source.   Additionally, Cymer shall provide certain NTE pricing, delivery,
and [...***...] commitments to Intel
in the event Intel elects to purchase Cymer EUV Source System(s) resulting from
such accelerated development; and

 

WHEREAS, In consideration of such commercial
provisions, Intel has provided funding and agrees to provide Cymer with certain
NRE funding under this Agreement  and has provided separate licenses to certain of
Intel’s patents related to EUV technology; and

 

WHEREAS, all purchases of EUV Source
System(s) developed, manufactured and made available to Intel hereunder shall
be in accordance with the terms of a Corporate Purchase Agreement and any
successor agreement thereto (“CPA”) and including all applicable EUV Source
System(s) Specific Addenda (“ESA”s). If applicable, Cymer shall cause its sales
subsidiaries to honor all sales related commitments made by Cymer under this
Agreement and cause such subsidiaries to offer for sale and sell such EUV
Source System(s) to Intel in accordance with the Agreement terms.

 

NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is acknowledged, the Parties agree as follows:

 

AGREEMENT

 

1.                                      CONSTRUCTION AND DEFINITIONS

 

1.1.                              Construction. 
All references in this Agreement to “Sections” refer to the
sections of this Agreement.  As used in
this Agreement, neutral pronouns and any variations thereof shall be deemed to
include the feminine and masculine and all terms used in the singular shall be
deemed to include the plural, and vice versa, as the context may require.  The words “hereof,” “herein”
and “hereunder” and other

 

*Confidential Treatment Requested

 

Confidential

 

1

 

words of similar
import refer to this Agreement as a whole, as the same may from time to time be
amended or supplemented, and not to any subdivision contained in this
Agreement.  This Agreement shall be construed
without regard to any presumption or other rule requiring construction hereof
against the Party causing this Agreement to be drafted.

 

1.2.                              Definitions. 
As used in this Agreement, the following capitalized terms have the
meanings provided below:

 

(a)                                  EUV Source System(s) shall mean a system including all
apparatus to deliver debris-free, in-band, collected photons to the
intermediate focus of the EUV lithography system, and as specified in the SOW,
including the following programs/generations of Cymer’s EUV Source System:

 

(i)                                     “Beta Minus Source” means a 15W – 20W EUV Source System as
defined in the SOW.

 

(ii)                                  Beta Source” means a 50W EUV Source System as defined
in the SOW.

 

(iii)                               “HVM Source” means a baseline 100W (or other mutually
agreed power level) EUV Source System used in High Volume Manufacturing (HVM)
as defined in the SOW.

 

(b)                                 Intellectual Property shall mean any or all of the following
and all rights in, arising out of, or associated with EUV Source
System(s):  (i) all United States and
foreign patents and utility models and applications therefor and all reissues,
divisions, renewals, extensions, provisionals, continuations and
continuations-in-part thereof, and equivalent or similar rights anywhere in the
world in inventions and discoveries (“Patents”); (ii) all trade secrets and
proprietary information; (iii) all copyrights, copyrights registrations and
applications therefor and all other rights corresponding thereto throughout the
world (“Copyrights”); (iv) all mask works, mask work registrations and
applications therefor, and any equivalent or similar rights in semiconductor
masks, layouts, architectures or topology (“Maskworks”); (v) all industrial
designs and any registrations and applications therefor throughout the world;
and (vi) any similar, corresponding or equivalent rights to any of the
foregoing anywhere in the world.

 

(c)                                  Non- Recurring Engineering Expense
(“NRE”) means
those monetary amounts payable by Intel upon Cymer’s completion and Intel’s
acceptance of the milestones indicated in the SOW.  The aggregate total of NRE payments under this Agreement shall
not exceed [...***...].

 

2

 

Total NRE milestone payments by calendar year
are anticipated to be [...***...].

 

(d)                                 Production Units shall mean EUV Source System(s) ready
for high volume manufacturing (“HVM”) and made available for sale by Cymer to
Intel and other third parties.

 

(e)                                  Statement of Work (“SOW”) means a statement of work, including the
milestones and associated NRE payments, decision points, specifications, and
resource levels required to meet the milestones, and including the dates for
delivery of the specific EUV Source System(s) and which shall be developed in
conjunction with each type of EUV Source System purchased from Cymer.

 

(f)                                  Technical Showstopper means a technical problem which prevents
the development of a Beta Minus Source, Beta Source, or HVM Source, due to the
laws of physics, or as otherwise mutually agreed by the Parties in
writing.   Upon identification of a
Technical Showstopper the Parties shall promptly meet and determine a mutually
acceptable course of action.  

 

2.                                      SCOPE OF WORK

 

2.1                                 Development
of EUV Source System(s).  Cymer
shall use its reasonable commercial efforts to develop the EUV Source System(s),
according to the Statements of Work (and the associated ESAs if applicable) and
mutually agreed upon by the Parties. 
Statements of Work shall be developed for each EUV Source System(s)
generation and shall include and address, without limitation, the following
areas:  [...***...].

 

2.2                                 Intel
Access and Assistance.  Cymer will
allow Intel reasonable access to Cymer’s EUV Source System(s) programs
addressed under this Agreement and, at Intel’s option, to grant Intel the
opportunity to have its personnel observe such programs if believed helpful or
necessary by Intel to meet Intel’s roadmap, schedule or performance
requirements.  In the event such
observation results in a decision by the Parties to collaborate on development
of other EUV programs beyond the scope of the current Statement(s) of Work, the
Parties shall enter into a separate collaboration agreement addressing such
collaboration, including without limitation, ownership of intellectual property
developed thereunder.

 

2.3                                 Coordination
with Intel Roadmaps.  Cymer agrees
to employ its reasonable commercial efforts to execute all EUV Source System
programs to meet Intel’s roadmap/schedule requirements. The Parties shall meet
and review such roadmap and schedule requirements in conjunction with the Executive
Meetings held during the Agreement Term.

 

2.4                                 Executive
Meetings.  Intel and Cymer agree
they will regularly schedule executive reviews of the EUV Source System(s)
technology development plan and the schedule (“Executive Meetings”).  The Executive Meetings will occur [...***...]
until Cymer

 

3

 

makes the first HVM Source available for
shipment.  The agenda of such Executive
Meetings will be mutually agreed in advance thereof, including without
limitations, roadmaps, schedule requirements, non-binding unit forecast,
waivers to [...***...] (such waiver(s) to be at Intel’s sole discretion),
resolution of corrective action requests to Intel’s reasonable satisfaction,
Cymer program spending/funding (including anticipated sale of Beta Minus Source
and Beta Source) and NRE payments (which may be changed by mutual agreement in
the event it appears to the Parties that new technical or commercial issues
warrant such change).  If necessary, the
timing of [...***...] as set forth in Section 5 shall be changed to align with any
agreed upon roadmap and/or schedule changes.

 

2.5                           Coordination of Efforts with Third Party
Suppliers. Cymer
agrees to engage, coordinate and work with other third party suppliers and sub
suppliers as necessary to complete the work contemplated in the SOW.  This may include, but is not limited to,
buying components from other suppliers, collaborating with other suppliers, or
licensing other supplier’s intellectual property.  Additionally, Cymer agrees, at its sole discretion, to evaluate
whether to work in the same manner with other third party suppliers with whom
Intel has undertaken EUV source or source component development efforts.

 

3.                                      HVM SOURCE PRICING

 

3.1                                 Not to Exceed Pricing for HVM Sources. 
Cymer agrees to meet Intel’s affordability targets by providing Not To
Exceed (“NTE”) pricing for HVM Source as set forth below:

 

3.1.1                        The Parties agree that the HVM Source pricing goal is
[...***...], however, Cymer agrees that the final HVM Source price will not exceed
[...***...].  The not to exceed price is
based on the following assumptions with regard to a [...***...] system:
[...***...].     To the extent that EUV
industry generally accepted EUV lithography tool models indicate that an HVM
Source of 100 watts (or other mutually agreed upon power level) would actually
deliver performance of [...***...] but the HVM Source is delivered under this
Agreement with a performance of less than 100 watts (or other mutually agreed
upon power level) [...***...]. (Example – HVM Source delivers performance of
[...***...].) Failure to meet the NTE pricing shall not be considered a material
breach of this Agreement provided such failure is due to a Technical
Showstopper based on the above stated assumptions.

 

3.2                               [...***...]

 

3.2.1       [...***...]

 

4

 

4.                                      TECHNICAL PROGRAM REVIEWS

 

4.1.                              Technical Program Reviews. Cymer shall provide Intel a [...***...]
technical program review for programs conducted in conjunction with the SOW.
Upon Intel’s request, such program review may be changed to a [...***...] review in
the event it appears that any program acceleration undertaken hereunder is in
any manner in jeopardy of meeting agreed upon milestones/schedules.

 

5.                                      INITIAL SHIP  DATES
AND PURCHASE OF EUV SOURCE SYSTEM(S)

 

5.1.                              Initial Ship Dates. 
Cymer agrees it will make available for shipment a Beta Minus Source to
Intel’s selected lithography tool integrator (or Intel, as mutually agreed) by
[...***...], a Beta Source by [...***...], and HVM Source by [...***...], with a target
date of [...***...]. Cymer agrees to review potential plans to accelerate the
delivery of the Beta Source.  The
aforementioned scheduled availability dates will be extended by a period of
[...***...] for Beta Minus Sources (and possible partial extension of less than
[...***...] for Beta Sources) if Cymer determines a [...***...].

 

5.2.                              Purchase of EUV Source System(s). 
Notwithstanding Section 12.1, the Parties acknowledge and agree the
terms and conditions regarding the sale of EUV Source System(s) by Cymer to
Intel will be governed by the terms of the then current CPA and any amendments,
EUV Source System(s) ESAs, Statements of Work and any mutually agreed upon
additions thereto.  Unless otherwise
expressly indicated, for the purpose of purchase and sale of EUV Source
System(s), any inconsistency between the terms of this Agreement, and the above
referenced agreement shall be resolved in accordance with the terms of this
Agreement.

 

5.3.                              Leadtime and Cancellation of Orders. 
For the initial [...***...] units of HVM Sources, the lead time for delivery
will be [...***...] After Receipt of Order (“ARO”).  There is no cancellation option for the first [...***...] of HVM
Sources, however, shipments may be rescheduled once for each such unit for a
period not to exceed [...***...].  For all
HVM Source sales after the initial [...***...], the leadtime for delivery will be
[...***...] ARO and the following cancellation table will apply:

 

Cancellation Table**

 

	
  DAYS FROM DELIVERY

  	
   

  	
  [...***...] cancelled units

  	
   

  	
  GREATER THAN [...***...]

  cancelled units

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  

 

5

 

Number of units cancelled is
during a 3 calendar month period (Jan – Mar, Apr – June, July – Sept, Oct –
Dec).

 

**  The applicable cancellation penalty shall be calculated as the
number of units canceled times the cancellation percentage times the unit
price.

 

5.4                                 EUV Source System(s) [...***...]. 
Cymer shall provide Intel with the following EUV Source System(s)
[...***...] with respect to the various EUV Source System(s) addressed below.  [...***...].

 

(a)                                  Beta Minus Sources. [...***...]

 

(b)                                  Beta Sources. [...***...]

 

(c)                                  HVM Sources. [...***...]

 

The specific methodology for administering the [...***...] will be
determined by [...***...].

 

5.5                                 [...***...] Additionally, in the event that
Cymer is ready to deliver the EUV Source System(s) addressed in Section 5.4
(a), (b) and (c) above and Intel’s selected lithography tool integrator is also
ready to accept such delivery and integrate the EUV Source System(s) into their
lithography tool but Intel is either not ready or elects not to issue a
purchase order for such EUV Source System(s) (or lithography tools from the
lithography tool supplier as the case may be), then [...***...].

 

6.                                       CONFIDENTIALITY

 

6.1.                              General.  Disclosures
of confidential and proprietary information by either Party to the other Party
pursuant to this Agreement shall be governed by the Intel Corporate
Non-disclosure Agreement (“CNDA”) number 6250027.

 

6.2.                              Confidentiality of Agreement and its
Terms.  The Parties hereto shall keep the existence
of this Agreement and its terms confidential and shall not now or hereafter
divulge these terms to any third party except: (a) with the prior written
consent of the other Party; (b) as otherwise may be required by law or legal
process, including to legal and financial advisors in their capacity of
advising a Party in such matters; (c) during the course of litigation, so
long as the disclosure of such terms and conditions are restricted in the same
manner as is the confidential information of other litigating parties; or
(d)  in confidence to its legal counsel,
accountants, banks and financing sources and their advisors solely in
connection with complying with financial transactions; provided that the
disclosing Party shall provide the other Party with at least 10 days prior
written notice of such disclosure and the opportunity to assist the other Party
in limiting the disclosure to the extent permissible under applicable law.

 

6

 

6.3.                              Neither Party may use the other Party’s
name or trademarks in advertisement, materials, web sites, press releases,
interviews, articles, brochures, banners, letterhead, business cards, project
reference or client listings, without the other’s prior review and written
consent.  Notwithstanding the foregoing,
it is the Parties mutual intent to develop and make a joint press announcement
with respect to the relationship undertaken pursuant to this Agreement.  Additionally, it is understood that the
parties may need to mention or refer to the other party’s name in conjunction
with responding to third party questions or inquiries regarding mutually
approved press releases, joint interviews, etc.  Any such use shall not be deemed to be a violation of this
provision provided such use is consistent with the mutually approved content
with respect to which it is undertaken.

 

7.                                      WARRANTIES, COVENANTS AND HOLD HARMLESS

 

7.1.                              General Warranty. 
Each Party hereby represents and warrants to the other that: (i) all
corporate action on the part of such Party, its officers, directors and
shareholders necessary for the authorization of this Agreement and the
performance of all obligations of such Party hereunder has been taken; and (ii)
this Agreement, when executed and delivered, will be a valid and binding
obligation of such Party.

 

7.2.                              No Conflict. 
Each Party hereby represents and warrants to the other that such Party’s
making of this Agreement and performance hereunder does not and will not
violate any agreement existing between such Party and any third party.

 

7.3.                              Commercial Hold Harmless. 
Both Parties recognize that the outcome of the business relationship
created by this Agreement is uncertain, and therefore this Agreement is not,
and shall not be construed as, a commitment by Intel to use Cymer’s products or
technology.

 

(a)                                  Except as otherwise specifically provided
in this Agreement under no circumstances shall either Party be liable to the
other for costs or damages of any kind, including without limitation,
incidental, consequential, special or speculative damages, lost profits or loss
of business, in connection with not proceeding with a business relationship
with Cymer.

 

(b)                                 The Parties acknowledge that it would be
imprudent and unreasonable to rely upon the expectation of conducting future
business together, and the Parties’ activities under this Agreement shall not
be considered evidence of intent to conduct future business.

 

(c)                                  Cymer acknowledges that Intel has a
policy of obtaining multiple qualified suppliers for equipment and materials
used in Intel’s manufacturing, and that Intel may choose to disengage from
working

 

7

 

with Cymer at
Intel’s sole discretion, irrespective of fault on Cymer’s part.

 

(d)                                 Neither Party shall be precluded from
evaluating, independently developing or marketing technology or products
similar to those that are the subject of this Agreement.

 

 7.4          [...***...]

 

8.                                      INTELLECTUAL PROPERTY

 

8.1.                            The Parties anticipate that there will be
Intellectual Property developed pursuant to the activities undertaken
hereunder.  Notwithstanding this
Agreement, all intellectual property developed independently by one Party shall
be owned by that Party. Intellectual Property developed jointly by the Parties
shall be owned as follows:

 

(a)                                  All Intellectual Property created
hereunder and directly related to the light sources for semiconductor
photolithography will be owned by Cymer.

 

(b)                                 All Intellectual Property created
hereunder and directly related to the photolithography process in the
manufacture of integrated circuits, or integrated circuits will be owned by
Intel.

 

(c)                                  All jointly developed Intellectual
Property hereunder that falls within both (a ) & (b) above or jointly
developed intellectual property that falls within neither of (a) nor (b) shall
be jointly owned.

 

8.2                                 [...***...]

 

9.                                      LIMITATION OF LIABILITY

 

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY
INCIDENTAL, CONSEQUENTIAL, INDIRECT, OR SPECIAL DAMAGES OF THE OTHER PARTY
ARISING OUT OF OR IN RELATION TO THIS AGREEMENT, EVEN IF THAT PARTY HAS BEEN
INFORMED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL CYMER’S
LIABILITY UNDER THIS AGREEMENT EXCEED AMOUNTS RECEIVED FROM INTEL HEREUNDER. 

 

10.                               TERM, TERMINATION AND SURVIVAL OF TERMS.

 

10.1.                        Term. This Agreement shall commence on the Effective Date
and shall terminate [...***...] following the first HVM Source made available for
shipment by Cymer to Intel or Intel’s designated lithography tool integrator,
unless earlier terminated as provided below or extended by mutual agreement
(such period, the “Term”).

 

8

 

10.2.                        Termination. 
Either Party may terminate this Agreement for any reason upon providing
the other Party with reasonable prior written notice.  Termination of the Agreement does not terminate other Applicable
Documents as set forth in section 12.2. The following additional terms shall
apply to any Agreement termination prior to the expiration of the Term:

 

(a)                                  If Intel cancels for convenience or the
Parties terminate the Agreement due to a Technical Showstopper in the
development under the SOW; Intel’s rights under Section 11.3 hereunder shall
not apply and Intel shall pay, on a pro-rata basis, for all work in progress
already performed by Cymer with regard to the next scheduled milestone, and
Cymer shall not owe any monies to Intel.

 

(b)                                 If Cymer cancels this Agreement for
convenience Cymer shall repay the NRE monies received.

 

(c)                                  If Cymer cancels this Agreement for cause
(other than a Technical Showstopper) due to a material breach of the Agreement
by Intel and such breach is not remedied within [...***...] of providing Intel with
written notice of such breach, Intel’s rights under Section 11.3 shall not
apply and Cymer shall not owe any monies to Intel. In the event that Intel
remedies such breach within [...***...], any resulting impact (direct or indirect)
to the SOW milestone schedule shall be addressed by the Parties.

 

(d)                                 If Intel cancels this Agreement for cause
(other than a Technical Showstopper) due to a material breach of the Agreement
by Cymer and the breach is not remedied within [...***...] of providing Cymer with
written notice of such breach, Intel’s rights under Section 11.3 shall apply.

 

10.3.                        If Cymer materially breaches this
Agreement, including [...***...] (except for causes beyond the control of Cymer),
or does not address the topics for agenda of the Executive Meetings as set
forth in Section 2.4, and the breach is not remedied within [...***...] of receipt
of written notice, then this Agreement shall immediately terminate
[...***...].  For clarity, a breach of
[...***...], or termination for convenience or termination due to a Technical
Showstopper are not a material breach of this Agreement.

 

10.4.                        Survival.  Sections 1,
3 (but only upon Agreement expiration as incorporated into a CPA), 6, 7 (but
Section 7.4 only upon Agreement expiration as incorporated into a CPA), 8.1, 9,
10 (to the extent needed to implement the rights and remedies set forth
therein), 11.1, 11.3 and 12 shall survive expiration or termination of this
Agreement for any reason. No termination or expiration of the Agreement shall
serve to terminate any EUV Source System purchase order issued by Intel

 

9

 

pursuant to the
terms of this Agreement prior to the effective date of such termination or
expiration.

 

11.                               FORCE MAJEURE, BUSINESS CONTINUITY AND LICENSE RIGHTS

 

11.1.                        Force Majeure. 
If the performance of this Agreement or any obligations hereunder (other
than payment of money) is prevented, restricted, or interfered with by the
reasons of acts of God, acts of an governmental authority, riot, revolution,
fires, or war, or other cause beyond the reasonable control of the Parties
hereto (“Force Majeure”), the Party so effected shall be excused from such
performance until such Force Majeure is removed, provided that the Party so
effected shall use its reasonable commercial efforts to avoid or remove such
causes of non-performance and shall continue performance hereunder with the
utmost dispatch whenever such causes are removed.

 

(a)                                  Adjustments. 
In the event that any delay in performance pursuant to this Section 11.1
extends for more than thirty (30) days, the Parties shall enter into good faith
discussions concerning changes in any milestone schedules.

 

11.2                     Business
Continuity Plans.  Cymer agrees to
develop alternate strategies for production in order to secure the continuation
of Cymer’s manufacturing capability in the case of Force Majeure or other
unforeseen events that could result in manufacturing disruption.

 

11.3                     License
Rights.  The rights set forth in
this paragraph shall apply if any of the following conditions (“Trigger
Events”) occur:

 

•                  Cymer enters
into bankruptcy or ceases to conduct business in the normal course.

•                  Cymer enters
into any agreement for the benefit of creditors.

•                  Cymer is unable
to obtain any necessary SEMI, CE or other similar safety and compliance
certifications.

•                  If Cymer causes
any material breach of the Agreement, such as a breach of contractual [...***...]
provisions with Intel, and such breach is not cured within [...***...] of receipt
of written notice.  For clarity, a
failure to [...***...] due to Force Majeure event(s) or or causes directly controlled
by Intel shall not be deemed a Trigger Event.

•                  Cymer fails to
[...***...].  In the event Cymer [...***...]
prior to the License Right obligation being triggered.  For clarity, the License Right is not
triggered if Cymer has cured the failed milestone within 6 months.

 

In case of a Trigger Event, Cymer shall grant to Intel the following
License Rights: [...***...].  Further, the
Parties agree to meet and discuss possible

 

10

 

ways to mitigate the impact of such Trigger Events to Intel.  The License Rights granted herein shall be
limited to [...***...] systems [...***...] only.

 

12.                               MISCELLANEOUS

 

12.1.                        Merger, Modification, Waiver. 
Except for the other applicable documents mentioned below in provision
12.2, this Agreement contains the entire understanding between Intel and Cymer
with respect to the subject matter hereof, and merges, and supersedes all prior
and contemporaneous agreements, dealings and negotiations.  No modification, alteration or amendment
shall be effective unless made in writing, dated and signed by duly authorized
representatives of both Parties.  No
waiver of any breach hereof shall be held to be a waiver of any other or
subsequent breach.

 

12.2.                        Other Applicable Documents. 
This Agreement shall incorporate by reference the following additional
terms: Intel Corporate Non Disclosure Agreement #6250027, a Corporate Purchase
Agreement and any successor agreement thereto (“CPA”) and including all
applicable EUV Source System Specific Addenda (“ESA”s) , and any applicable
amendments or additions to the foregoing (“Appliable Documents”). [...***...]

 

12.3.                        Choice of Law and Jurisdiction. 
This Agreement shall be governed by and construed in accordance with the
laws of the State of California, without reference to its conflicts of law
principles.  Each Party hereby agrees to
jurisdiction and venue in the courts of the State of California or federal
courts located in California for all disputes and litigation arising under or
relating to this Agreement.

 

12.4.                        Relationship of the Parties. 
This Agreement is not intended to be, nor shall it be construed as, a
joint venture, association, partnership, franchise or other form of business
relationship.  Neither Party shall have
nor hold itself out as having any right or power or authority to assume,
create, or incur any expense, liability or obligation, expressed or implied, on
behalf of the other Party, except as expressly provided herein.  Except as expressly agreed, each Party shall
bear its own costs and expenses incurred under or in conjunction with its
performance of its obligation contained in this Agreement.

 

12.5.                        Assignment.  During the
Agreement Term the rights and obligations of the Parties under this Agreement
may not be assigned, whether by operation of law or otherwise, without the
prior written consent of the other Party, which consent may not be unreasonably
withheld. Any such attempted assignment shall be null and void. Notwithstanding
the foregoing, Intel shall be allowed to unilaterally assign this Agreement to
any of its wholly owned subsidiaries upon written notice to Cymer.   Each Party reserves the right to withhold
any required consent if in its good faith reasonable judgment, the proposed
assignee in not capable of meeting the rights and obligations under the
Agreement.  Subject to the foregoing,
this

 

11

 

Agreement shall
inure to and benefit and bind the successors and permitted assigns of the
Parties.

 

12.6.                        Notices.  All notices,
demands or consents required or permitted hereunder shall be in writing and
shall be delivered, sent by facsimile (with confirmation copy by mail) or
telex, or mailed to the respective Parties at the addresses first set forth in
the first paragraph of this Agreement or at such other address as shall have
been given to the other Party in writing for the purposes of this clause.  Such notices and other communications shall
be deemed effective upon the earliest to occur of (i) actual delivery, (ii)
five (5) days after mailing, addressed and postage prepaid, returned receipt
requested, as aforesaid, or (iii) one (1) business day after transmission by
telex, telegram or facsimile where receipt has been confirmed by the same type
of transmission or in writing received by the sender.

 

12.7.                        Severability. 
The provisions of this Agreement are severable and if any one or more
such provisions shall be determined to be invalid, illegal or unenforceable, in
whole or in part, the validity, legality and enforceability of any of the
remaining provisions or portions thereof shall not in any way be affected or
impaired thereby and shall nonetheless be binding between the Parties hereto.

 

12.8.                        Titles and Headings. 
Titles and headings to Sections herein are inserted for convenience of
reference only and are not intended to affect the meaning or interpretation of
this Agreement.

 

12.9.                        Dispute Resolution. 
All disputes arising directly under the express terms of this Agreement
or the grounds for termination thereof shall be resolved as follows:  The senior management of both Parties shall
meet to attempt to resolve such disputes. 
If the senior management cannot resolve the disputes, either Party may
make a written demand for formal dispute resolution and specify therein the
scope of the dispute.  Within thirty
(30) days after such written notification, the Parties agree to meet for one
(1) day with an impartial mediator and consider dispute resolution alternatives
other than litigation.  If an
alternative method of dispute resolution is not agreed upon within thirty (30)
days after the one day mediation, either Party may begin litigation
proceedings.

 

12.10.                  Liquidated Damages. Subject to the terms of Sections 9 &
10 of this Agreement, [...***...].

 

12.11.                  Payments. Unless expressly indicated otherwise, all payments
due and payable by a Party shall be made within thirty (30) days of the due
date.

 

12.12.                  Counterparts. 
This Agreement may be executed in multiple counterparts, each of which
shall be deemed an original, but all of which shall constitute one and the same
instrument.

 

12

 

IN WITNESS WHEREOF, the Parties have caused this Agreement
to be executed by duly authorized officers or representatives to be effective
as of the date first above written.

 

	
  INTEL
  CORPORATION

  	
  CYMER, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By: 

  	
  /s/ CHRIS
  PHILIPPI 

  	
   

  	
  By:

  	
  /s/ ROBERT
  P. AKINS

  
	
   

  	
   

  
	
  Name: 

  	
  Chris
  Philippi

  	
   

  	
  Name:

  	
  Robert P.
  Akins

  
	
   

  	
   

  
	
  Title:

  	
  Business
  Manager

  	
   

  	
  Title:

  	
  CEO

  
	
   

  	
   

  
	
  Date:

  	
  January 28th,
  2004

  	
   

  	
  Date:

  	
  January 23,
  2004

  
										

 

13

 

Exhibit A:

 

STATEMENT OF WORK & NRE PAYMENT
MILESTONES

 

14

 

Addendum A

 

Project Prism
Statement of Work

Cymer [...***...] EUV Source
System Development

 

Objectives of the program:

 

•                  Evaluate design
concepts to produce a robust [...***...] EUV light source to support production
semiconductor EUV lithography.

 

•                  Develop Beta Minus  (15 Watt) [...***...] EUV
prototype light source system to support early generation EUV Lithography
scanner tools [...***...]

 

•                  Develop Beta  (50
Watt) [...***...] EUV light source to support process development EUV
Lithography scanner tools [...***...]

 

•                  Develop HVM (high volume manufacture) (100 Watt) [...***...] EUV light source to support production generation EUV Lithography
scanner tools [...***...]

 

Project Roadmap (top level planning):

 

[...***...]

 

0.               Administrative/Planning

Cymer and Intel will hold, at a minimum, [...***...] phone meetings and [...***...]
face-to-face progress review meetings. The time and place of the meetings will
be determined later.  At every second
progress review meeting, Cymer and Intel will assess the scope and direction of
the remaining part of the agreement and will mutually agree to changes in the
tasks, deliverables, or overall direction, as required.  Both parties recognize at the inception of
this aggressive development program that changes in this SOW (including any
detailed specifications cited) may be required due to unforeseen circumstances
or changing priorities.  Cymer will make
all reasonable efforts to meet the spirit of the tasks to best advance the
overall progress in EUV light source development in support of the Intel’s [...***...] roadmap. 
On an annual basis, Cymer and Intel will complete a technology risk
assessment towards achieving HVM EUV source output power and cost-of-ownership
requirements.  This assessment will take
into account any new information made available since the last risk assessment.
The external development agreements referenced in the tasks below will be
thoroughly evaluated and prioritized over the first [...***...] of the contract.  At the first face to face progress review, Cymer will review all
of the external development agreements and the development plans which will
cover [...***...] system assemblies,
labs, schedules, external contracts, etc.

 

1

 

With Intel’s assistance, Cymer will develop a EUV cost of ownership
model to determine the financial feasibility of the “best” EUV source
technology path selected.  These results
will be reviewed at each scope assessment review meeting outlined above.

 

0.1.1.    Collaboration
kickoff [...***...]

 

0.1.2.    Comprehensive
plan for external development agreements [...***...]

 

0.1.3.    Review detailed
program plan [...***...]

 

0.1.4.    End Year 1
Executive Review [...***...]

 

0.1.5.    Review revised
detailed program plan for 50 W Beta [...***...]

 

0.1.6.    End Year 2
Executive Review [...***...]

 

0.1.7.    Mid Year 3
Executive Review [...***...]

 

0.1.8.    Review revised
detailed program plan for 100W HVM [...***...]

 

0.1.9.    End Year 3
Executive Review [...***...]

 

1.     Evaluate
design concepts to produce a robust [...***...] EUV light source [...***...]

 

During the
first [...***...] of the
contract, there will be a focus on the investigation of basic concepts and
critical issues that will affect the overall technical direction of the
development of HVM light sources.  These
basic studies will lead to the construction of an initial EUV [...***...] source capable of demonstrating key
performance parameters relevant for the successful implementation of HVM EUV
lithography.  This prototype system will
contain [...***...] defined through
a series of concept and feasibility (C&F) investigations in each critical
area of the [...***...] light source
system: [...***...].  Each C&F study is intended to quickly
probe the relevant issues in their respective disciplines with the goal of
determining the “best” path for the [...***...] and Beta Minus level sources.  An
initial expected configuration of these elements would be an [...***...]. 
Additionally, [...***...]
equipment will be constructed to verify EUV source output power.  This [...***...] prototype system will be able to produce the equivalent of [...***...] at the intermediate focus at full geometric
efficiency and will serve as a good early representation of the [...***...] technology that will be required for the HVM
solution.

 

1.1. Assembly and
test of [...***...] system [...***...]

 

2

 

Cymer
will design, assemble, and test an [...***...] system [...***...] based on the results of the C&F investigations performed in each of
the critical technical areas of the overall system. This [...***...] will allow the first measurements of system
level performance to understand the overall integration and interdependency of
the individual system components.

 

Technical Milestones/Deliverables

 

1.1.1.    Operational
[...***...] prototype EUV source system [...***...]

 

1.1.2.    Data Review of
[...***...] prototype system performance [...***...]

 

1.2. Determination of
[...***...] for [...***...] generation

 

Cymer will evaluate suitable [...***...] candidates to support [...***...] development.  Initial experiments will be made using a [...***...]. 
Access to [...***...] will be
investigated with external suppliers and incorporated into the test plan as
required.  [...***...].  Cymer
will acquire or build metrology equipment to collect data on EUV source
operating parameters.  Additional data
on other EUV source parameters may be collected, as required or by mutual
agreement between Cymer and Intel.

 

1.2.1.    Build [...***...] evaluation [...***...]

 

Cymer
will design and assemble a [...***...] for evaluation of critical EUV [...***...] requirements. The [...***...]
will be based on the [...***...]
setup and will be able to deliver up to [...***...].  Additionally, Cymer will
acquire a commercial, [...***...].  The [...***...] allowing the investigation of [...***...] as a function of [...***...]
and will allow comparison of the results from the [...***...]. 
Cymer will also assemble a [...***...] with [...***...] quality to
investigate operational issues for a [...***...] at these performance levels.

 

Technical Milestones/Deliverables

 

1.2.1.1.       Commercial [...***...]
operational [...***...]

 

1.2.1.2.       [...***...] operational [...***...]

 

1.2.1.3.       [...***...] operational [...***...]

 

1.2.1.4.       [...***...] operational [...***...]

 

1.2.1.5.       [...***...] operational [...***...]

 

3

 

1.2.2.    Gain access to [...***...]

 

Cymer
will attempt to establish a working agreement (if required), which allows
access to a [...***...], for EUV source power scaling experiments.

 

Technical Milestones/Deliverables

 

1.2.2.1.       Agreement
in place for access to [...***...] for [...***...] evaluation experiments [...***...]

 

1.2.3.    Determine optimum [...***...] requirements

 

[...***...]

 

Technical
Milestones/Deliverables

 

1.2.3.1.       Review
published literature on benefits of [...***...]

 

1.2.3.2.       Determine
the optimum requirements for the [...***...]

 

1.2.3.3.       Data
review leading to recommendation of [...***...]

 

1.2.3.4.       Develop
[...***...] system [...***...] in section 1.1.1 [...***...]

 

1.3.  Determination
of optimum source element and delivery for [...***...]

 

[...***...] elements have become the favored
technical approach to reaching higher EUV power output through [...***...].  Previous work at Cymer, and results from the
industry, indicate that [...***...] are excellent prospects for higher efficiency
at [...***...].  This result for [...***...] has
been recently confirmed at several independent labs.  Other than our early [...***...] investigations, the use of [...***...]
as a viable source element has so far been ignored in both [...***...] and [...***...]
EUV source applications.  A [...***...],
based on Cymer’s [...***...], (see section 1.2.1) will be constructed to carry out
direct studies of EUV emission from [...***...] targets.  Initially, the [...***...] will be used to probe the [...***...].  These experimental results will also be
compared to modeling to determine if [...***...] is warranted.  After this initial C&F period to verify
the fundamental CE properties of these [...***...] materials, a more complex
[...***...] system will be developed and introduced.  Further investigations will then be performed to optimize CE
approaching the theoretical maximum determined by modeling.  Critical variables such as [...***...] along
with target delivery parameters such as [...***...], etc will be examined to
determine the optimum system architecture for further development.

 

4

 

1.3.1.    Determine fundamental source
element conversion efficiency

 

A [...***...] will be constructed
to carry out direct studies of EUV emission from [...***...] targets.  The [...***...] will be used to probe the
intrinsic conversion efficiency.  CE
metrology will be benchmarked to performance on Cymer’s [...***...] source.
Additionally, Cymer will investigate external collaborations for validation of
CE measurements.  It is currently
thought that demonstration of a conversion efficiency of greater than [...***...]
will be required to satisfy HVM power and commercial considerations.

 

Technical
Milestones/Deliverables

 

1.3.1.1.       Preliminary review of
[...***...] (and others as available) source element conversion efficiency [...***...]

 

1.3.1.2.       Evaluate
a development agreement with [...***...] (or other suitable group) to probe the CE as a function of several
parameters: [...***...]

 

1.3.1.3.       Determination of optimal
source element based on studies of intrinsic conversion efficiency and [...***...]
concerns [...***...]

 

1.3.2.    Construct [...***...] source
element [...***...]

 

The
initial [...***...] source element [...***...] will allow for simple experiments with [...***...] materials to investigate intrinsic CE of
materials such as [...***...].  This will be followed by an investigation
into the various methods to produce [...***...] source element [...***...].

 

Technical Milestones/Deliverables

 

1.3.2.1.       A
simple [...***...] source element [...***...] compatible with different source elements
operational [...***...]

 

1.3.3.    Source element delivery and
recovery

 

Cymer
will evaluate the [...***...]
elements and [...***...]
concepts.  Cymer will also evaluate
suitable [...***...] (section
1.3.2), [...***...] to support [...***...]. 
These experiments will take into account the variables evaluated under
the [...***...].  Cymer will investigate

 

5

 

various techniques
for delivering [...***...].  These studies will culminate with the
construction of a [...***...] to be
incorporated into the system [...***...].  Key operational variables such
as [...***...] will be
considered.  Other considerations will
be [...***...] etc.

 

Technical Milestones/Deliverables

 

1.3.3.1.       Data
review on the various techniques to produce [...***...] and recommendation of “best” concepts [...***...]

 

1.3.3.2.       Evaluate
a development agreement with [...***...] (or other suitable group) to probe the [...***...]

 

1.3.3.3.       Preliminary data review on
[...***...]

 

1.3.3.4.       Final Data review leading
to the recommendation of [...***...]

 

1.3.3.5.       [...***...] source operational [...***...]

 

1.3.4.    Develop [...***...] model with [...***...]

 

Cymer
will initiate [...***...] at [...***...] (or other suitable group) to determine [...***...].  The
objective of this work is to develop a predictive model, which agrees with
experimental results to further optimize overall CE performance.

 

Technical
Milestones/Deliverables

 

1.3.4.1.       Evaluate
a development agreement for [...***...]

 

1.3.4.2.       Objectives
for [...***...] defined [...***...]

 

1.3.4.3.       Data
review of initial [...***...]
progress and comparison to experimental results [...***...]

 

1.4.         Debris
Mitigation and [...***...] Technology

 

Debris mitigation encompasses physical debris
generated from the operation of the EUV source (especially with [...***...]) and debris that degrades the optical
components within the system. It also includes contamination from all sources
in the system (such as [...***...])
which may interact with optical components causing degradation [...***...], or sputtering of other surfaces induced by [...***...] from the [...***...]. These mechanisms can contribute to the
degradation of the system efficiency by either directly sputtering the [...***...] and/or [...***...].  Cymer will evaluate effective
debris mitigation techniques including [...***...] to mitigate the effects of the above mechanisms.

 

6

 

Cymer will also evaluate the [...***...] with several witness samples. [...***...] is known to be highly reactive with most
materials, so Cymer will also investigate manufacturing methods and materials
that are immune to these reactive effects. 
A critical question that will be answered during this initial phase of
investigation is whether [...***...]
can be fully removed from the [...***...] without damage and if some [...***...] remain, whether they can be removed non-destructively.  Further, Cymer will investigate
contamination protection techniques to prevent contamination of other system
optics such as the [...***...].  Cymer will also design a “clean” [...***...] that minimizes the sources of contamination
and allows for easy serviceability of all of the consumable components.  This vessel will be an integral part of the [...***...] system and will house the [...***...] system, the [...***...] system, and all necessary [...***...] to verify system performance.

 

Technical
Milestones/Deliverables

 

1.4.1.1.       Obtain a [...***...] for
contamination experiments [...***...]

 

1.4.1.2.       Evaluation of debris issues
and concepts to mitigate [...***...]

 

1.4.1.3.       [...***...] standards developed
for debris measurement [...***...]

 

1.4.1.4.       Debris mitigation concepts
review [...***...]

 

1.4.1.5.       Review results from
contamination experiments [...***...]

 

1.4.1.6.       Contract for [...***...] awarded
[...***...]

 

1.4.1.7.       Completed debris mitigation
[...***...] integrated into [...***...]

 

1.4.2.    Determination
of [...***...] sputter yield on [...***...]

 

[...***...] generated from the [...***...] are a great concern to lifetime of the [...***...] of the [...***...].[...***...] have been shown
to destroy the [...***...] through a
[...***...].  No data to date has been taken on the
generation of [...***...].  Cymer will measure [...***...] emitted from the [...***...] and assess their impact on [...***...]. 
Cymer will form a development agreement with the [...***...] (or other suitable group) to determine the [...***...] of [...***...] on [...***...].

 

Technical
Milestones/Deliverables

 

1.4.2.1.       Evaluate
a development agreement with [...***...] (or other suitable group) to measure [...***...] on [...***...]

 

1.4.2.2.       Objectives
for [...***...] work defined [...***...]

 

7

 

1.4.2.3.       Review
initial results on [...***...]

 

1.4.3.    [...***...] studies

 

While it is thought that [...***...] will protect it from [...***...], other [...***...] have much [...***...].  Cymer will investigate [...***...] and their effectiveness at removing [...***...] and other sources of contamination while not
damaging the delicate [...***...]

 

Technical
Milestones/Deliverables

 

1.4.3.1.       Evaluate
a development agreement with [...***...] (or other suitable group) to perform [...***...]

 

1.4.3.2.       [...***...] experimental setup constructed [...***...]

 

1.4.3.3.       Review
results of [...***...]

 

1.4.4.    [...***...] Assembly

 

A
critical element in the efficiency of the EUV light source system is the
ability to [...***...].  There are many critical technologies around
the development of a [...***...].  These include: [...***...].  Due
to the critical nature of [...***...]
and its effect on the system cost of ownership, Cymer will investigate the [...***...]. Considerations such as [...***...] are intertwined with some of the [...***...] issues also to be addressed.  Cymer will establish a development agreement
to produce an integrated [...***...],
determine the most suitable [...***...]. In addition, Cymer will try to integrate a [...***...] assembly. Development of [...***...] capable of [...***...] will also be investigated.

 

1.4.5.    [...***...] design

 

Technical
Milestones/Deliverables

 

1.4.5.1.       [...***...] completed [...***...]

 

1.4.5.2.       Contract
for [...***...] in place. [...***...]

 

1.4.5.3.       [...***...] completed [...***...]

 

1.4.6.    [...***...] fabrication

Technical Milestones/Deliverables

 

1.4.6.1.       Data review on based on
completion and testing of a [...***...]

 

8

 

1.4.6.2.       Completed [...***...]

 

1.4.6.3.       Completed [...***...]

 

1.4.7.    [...***...]

 

A critical element in the conceptual design
of an [...***...] system
using [...***...], as a source
element, is the need to keep the [...***...] of any [...***...].  This is accomplished by [...***...]. 
Development of a [...***...]
is required.  Cymer proposes
establishing a development agreement with the [...***...] (or other suitable group) to do fundamental
research in [...***...]. This
agreement will also allow the [...***...] to be applied to test samples sent to Cymer for [...***...]. 
Another potential limitation of [...***...] is [...***...]. This effect
will be evaluated at [...***...].

 

Technical Milestones/Deliverables

 

1.4.7.1.       Attempt to establish [...***...]

 

1.4.7.2.       Preliminary results for
[...***...]

 

1.4.7.3.       Delivery of initial samples
to Cymer for [...***...]

 

2.              Beta
Minus (15 Watt) [...***...] EUV source prototype to support early generation EUV
scanner development [...***...]

 

Cymer will apply its
five-phase stage-gate Product Development Process (PDP) to reduce the schedule
risk for the first shipping system; the 15 W Beta Minus prototype.  Since this system is a single unit prototype
not destined for full production, only PDP phases 1-3 will be required.  At the end of the C&F investigations in
section 1 (near the completion of PDP Phase 1 Concept
and Feasibility), Cymer will formalize a specific and discrete
product development program with the objective of delivering a 15W  [...***...] source system to a [...***...] in the [...***...].  During PDP phases 2 (Demonstration) and 3 (Product Design), several internal [...***...] source system prototypes each with
successively improved performance and capability will be constructed.  (The initial system [...***...]
is described in section 1.1.)  In PDP phase 2, performance of all critical technologies
together in a complete system will be demonstrated.  Early in PDP phase 3, the configuration of the shipping system
will be frozen in preparation for shipment.  
In addition, the performance specification for the shipping system will
be finalized in Phase 3 and the 15W [...***...] source system will be built and tested per the agreed upon
specification with the Integrator.

 

The preliminary target
specifications for a 15W Beta minus source are provided in Table 1. These specifications will be used to
evaluate progress against milestones in the absence of specifications from

 

9

 

the integrators. These
target specifications can be modified based on discussions with the integrators
or by mutual agreement between Intel and Cymer.  Cymer will work with the Integrators to develop the appropriate
detailed performance specifications, test protocol, interface requirements, and
roadmap alignment to integrate the Beta Minus source into the Integrator’s
early EUV development plans. Intel will assist in roadmap and specification
alignment discussion with the Integrator, as needed. Cymer will develop the
necessary supply base to support development of the Beta Minus source.

 

Technical
Milestones/Deliverables

 

2.1.1.1.   PDP phase 1 gate review
completed and approval to proceed to PDP phase 2 granted [...***...]

 

2.1.1.2.       Source system [...***...]
operational and demonstrate performance of critical technologies [...***...]

 

2.1.1.3.       Establish 15W prototype
[...***...] source specification with [...***...]

 

2.1.1.4.       15W [...***...] source system
shipping configuration established [...***...]

 

2.1.1.5.       PDP phase 2 gate review
completed and approval to proceed to PDP Phase 3 granted [...***...]

 

2.1.1.6.       Make available to ship 15W
Beta Minus [...***...] source to integrator [...***...]

 

3.              Develop Beta (50 Watt) [...***...] EUV light source to support process development EUV
Lithography scanner tools [...***...]

 

Cymer will apply its
five-phase stage-gate Product Development Process (PDP) to reduce the schedule
risk for the 50 W Beta source.  Since
this system is not destined for full production, only PDP phases 1-3 will be
required.  Near the completion of PDP
Phase 1 Concept and Feasibility,
Cymer will formalize a specific and discrete product development program with
the objective of delivering a 50W  [...***...] source system to a [...***...] at the [...***...].  In PDP phase 2, performance
of all critical technologies together in a complete system will be
demonstrated.  Early in PDP phase 3, the
configuration of the shipping system will be frozen in preparation for the
shipment.   In addition, the performance
specification for the shipping system will be finalized in Phase 3 and the 50W [...***...] source system will be built and tested per
the agreed upon specification with the Integrator.

 

The preliminary target
specifications for a 50W Beta source are provided in Table 1. These specifications will be used to
evaluate progress against milestones in the absence of specifications from the
integrators. These target specifications can be modified based on discussions
with the integrators or by mutual agreement between Intel and Cymer.  Cymer will work with the Integrators to
develop the appropriate detailed performance specifications, test protocol, interface
requirements, and roadmap alignment to integrate the Beta source into the
Integrator’s EUV development plans. 
Intel will assist in roadmap and

 

10

 

specification alignment
discussion with the Integrator, as needed. 
Cymer will develop the necessary supply base to support development of
the Beta source.

 

3.1.1.    Technical Milestones/Deliverables

 

3.1.1.1.       PDP Phase 1 Gate Review
completed and approval to proceed to PDP Phase 2 granted [...***...]

 

3.1.1.2.       Establish Beta 50W [...***...]
Source Specification with [...***...]

 

3.1.1.3.       Demonstrate 50W performance
internally [...***...]

 

3.1.1.4.       50W [...***...] Source System
shipping configuration established [...***...]

 

3.1.1.5.       PDP Phase 2 Gate Review
completed and approval to proceed to PDP Phase 3 granted [...***...]

 

3.1.1.6.       Make Available to Ship 50W
Beta [...***...] Source to Integrator [...***...]

 

4.              Develop HVM (high
volume manufacture) (100 Watt) [...***...]
EUV light source to support production
generation EUV Lithography scanner tools  [...***...]

 

Cymer will apply use its five-phase
stage-gate Product Development Process (PDP) to reduce the schedule risk for
the 100 W HVM source.  Near the
completion of PDP Phase 1 Concept and
Feasibility, Cymer will formalize a specific and discrete product
development program with the objective of delivering a 100W [...***...] source system to a [...***...] at the [...***...].  In PDP phase 2, performance
of all critical technologies together in a complete system will be
demonstrated.  Early in PDP phase 3, the
configuration of the shipping system will be frozen in preparation for the
first shipment and the initial life tests are commenced.   In addition, the performance specification
for the shipping system will be finalized in Phase 3 and the 100W [...***...] source system will be built and tested per
the agreed upon specification with the Integrator.  In PDP phase 4 Pilot
Production; the first systems are shipped in limited quantity with
special attention to meeting initial performance specifications and collection
of the first field data.  In PDP phase 5
Production, the field and life
test data are used to improve the final product that is then ramped to
production levels matched to demand.

 

The preliminary target
specifications for a 100W HVM source are provided in Table 1. These specifications will be used to
evaluate progress against milestones in the absence of specifications from the
integrators. These target specifications can be modified based on discussions
with the integrators or by mutual agreement between Intel and Cymer.  Cymer will work with the Integrators to
develop the appropriate detailed performance specifications, test protocol,
interface requirements, and roadmap alignment to integrate the Beta source into
the Integrator’s EUV development plans. 
Intel will assist in

 

11

 

roadmap and specification
alignment discussion with the Integrator, as needed.  Cymer will develop the necessary supply base to support
development of the Beta source.

 

4.1.1.    Technical Milestones/Deliverables

 

4.1.1.1.       PDP Phase 1 Gate Review
completed and approval to proceed to PDP Phase 2 granted [...***...]

 

4.1.1.2.       Establish 100W Prototype
[...***...] Source Specification with [...***...]

 

4.1.1.3.       100W  [...***...] Source System shipping
configuration established [...***...]

 

4.1.1.4.       PDP Phase 2 Gate Review
completed and approval to proceed to PDP Phase 3 granted [...***...]

 

4.1.1.5.       PDP Phase 3 Gate Review
completed and approval to proceed to PDP Phase 4 Pilot Production granted [...***...]

 

4.1.1.6.       Make Available to Ship
initial 100W HVM [...***...] Source to Integrator [...***...]

 

4.1.1.7.   PDP Phase 4 Gate Review
completed and approval to proceed to PDP Phase 5 Production granted [...***...]

 

12

 

Table 1 [...***...] EUV Source Preliminary Target Specifications
(top level)

 

	
   

  	
   

  	
  Beta Minus

  	
   

  	
  Beta

  	
   

  	
  HVM

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  	
  [...***...]

  	
   

  

 

* The [...***...] are based on [...***...] of the source at [...***...] and at [...***...] for the # of
hours specified with no more than [...***...] in the average [...***...] and no more than [...***...]. These specs will
be demonstrated on an actual system based on testing protocols consistent with
integrator requirements. [...***...]. This accounts for losses due to the [...***...]. Both Intel and
Cymer agree that these specifications are the best known to date and will be
modified based on discussions with the tool integrators or as more data becomes
available.

 

13

 

Payment Milestones

 

	
  Date

  	
   

  	
  Task #

  	
   

  	
  Milestones

  	
   

  	
  Payment

  $US

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.1

  	
   

  	
  •      Collaboration “kick-off”

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.2

  0.1.3

  	
   

  	
  •      Comprehensive plan for external
  development agreements

  •      Review detailed program plan

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.2.1.3

  	
   

  	
  •      [...***...] operational

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.2.3.3

  	
   

  	
  •      Data review leading to the
  recommendation of [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.3.1.3

  	
   

  	
  •      Determination of optimal source element
  based on studies of intrinsic conversion efficiency and [...***...].

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.3.3.4

  	
   

  	
  •      Final Data review leading to the
  recommendation of [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.4.1.7

  	
   

  	
  •      Completed debris mitigation [...***...]
  integrated into [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.1.1  1.1.2

  	
   

  	
  •      Operational
  [...***...] prototype EUV system

  •      Data
  Review of [...***...] prototype system performance

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.4.6.4

  	
   

  	
  •      Completed [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  2.1.1.3

  	
   

  	
  •      Establish 15W prototype [...***...] source
  specification with [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  1.2.1.4

  	
   

  	
  •      [...***...] operational

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  2.1.1.6

  	
   

  	
  •      Make available to ship 15W Beta minus
  [...***...] source to integrator

  •      15W beta minus source tested to meet all
  Table 1 specifications including demonstrated operation at full EUV output
  over the course of the full [...***...] lifetime.

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.5

  	
   

  	
  •      Beta PDP Phase I Gate Review completed
  and approval to proceed to PDP Phase 2 granted

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.6

  	
   

  	
  •      End Year 2 Executive review

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  3.1.1.2

  	
   

  	
  •      Establish Beta 50W [...***...] source
  specifications with [...***...]

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  3.1.1.3

  	
   

  	
  •      Demonstrate 50W performance internally

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.7

  	
   

  	
  •      Mid Year 3 Executive review

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  3.1.1.4  4.1.1.1

  	
   

  	
  •      50W [...***...] source system shipping
  configuration established.

  •      HVM PDP Phase I Gate Review Completed
  and approval to proceed to PDP Phase 2 granted.

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  3.1.1.6

  	
   

  	
  •      Make Available to Ship 50W Beta [...***...]
  Source to [...***...]

  •      50W beta minus source tested to meet all
  Table 1 specifications including demonstrated operation at full EUV output
  over the course of the full [...***...] lifetime.

  	
   

  	
  [...***...]

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  [...***...]

  	
   

  	
  0.1.9

  	
   

  	
  •      End Year 3 Executive review

  	
   

  	
  [...***...]

  	
   

  

 

Payments shall be made in full
within [...***...] after completion of milestones

 

[...***...]

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]